305 related articles for article (PubMed ID: 34830822)
1. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.
Pizzi M; Croci GA; Ruggeri M; Tabano S; Dei Tos AP; Sabattini E; Gianelli U
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830822
[TBL] [Abstract][Full Text] [Related]
2. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Barbui T; Thiele J; Gisslinger H; Kvasnicka HM; Vannucchi AM; Guglielmelli P; Orazi A; Tefferi A
Blood Cancer J; 2018 Feb; 8(2):15. PubMed ID: 29426921
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Agarwal MB; Malhotra H; Chakrabarti P; Varma N; Mathews V; Bhattacharyya J; Seth T; Gayathri K; Menon H; Subramanian PG; Sharma A; Bhattacharyya M; Mehta J; Vaid AK; Shah S; Aggarwal S; Gogoi PK; Nair R; Agarwal U; Varma S; Prasad SV; Manipadam MT
Indian J Med Paediatr Oncol; 2015; 36(1):3-16. PubMed ID: 25810569
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology of myeloproliferative neoplasms.
Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
6. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Tefferi A; Vardiman JW
Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
[TBL] [Abstract][Full Text] [Related]
7. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Wadleigh M; Tefferi A
Int J Hematol; 2010 Mar; 91(2):174-9. PubMed ID: 20191332
[TBL] [Abstract][Full Text] [Related]
8. Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.
Tremblay D; Yacoub A; Hoffman R
Hematol Oncol Clin North Am; 2021 Apr; 35(2):159-176. PubMed ID: 33641861
[TBL] [Abstract][Full Text] [Related]
9. Deactylase inhibition in myeloproliferative neoplasms.
Mithraprabhu S; Grigoriadis G; Khong T; Spencer A
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S50-7. PubMed ID: 21127942
[TBL] [Abstract][Full Text] [Related]
10. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative Neoplasms in Children.
Hofmann I
J Hematop; 2015 Sep; 8(3):143-157. PubMed ID: 26609329
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
13. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
14. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
15. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
16. The spectrum of JAK2-positive myeloproliferative neoplasms.
Kiladjian JJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():561-6. PubMed ID: 23233635
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of neutrophilic myeloid neoplasms.
Schwede M; Gotlib J; Shomali W
Clin Adv Hematol Oncol; 2021 Jul; 19(7):450-459. PubMed ID: 34236344
[TBL] [Abstract][Full Text] [Related]
18. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
19. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.
Ajufo HO; Waksal JA; Mascarenhas JO; Rampal RK
Ther Adv Hematol; 2023; 14():20406207231177282. PubMed ID: 37564898
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
